Cargando…

Functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin

INTRODUCTION: Dysferlin loss‐of‐function mutations cause muscular dystrophy, accompanied by impaired membrane repair and muscle weakness. Growth promoting strategies including insulin‐like growth factor 1 (IGF‐1) could provide benefit but may cause strength loss or be ineffective. The objective of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Barton, Elisabeth R., Pham, Jennifer, Brisson, Becky K., Park, SooHyun, Smith, Lucas R., Liu, Min, Tian, Zuozhen, Hammers, David W., Vassilakos, Georgios, Sweeney, H. Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771521/
https://www.ncbi.nlm.nih.gov/pubmed/31323135
http://dx.doi.org/10.1002/mus.26641
_version_ 1783455700785037312
author Barton, Elisabeth R.
Pham, Jennifer
Brisson, Becky K.
Park, SooHyun
Smith, Lucas R.
Liu, Min
Tian, Zuozhen
Hammers, David W.
Vassilakos, Georgios
Sweeney, H. Lee
author_facet Barton, Elisabeth R.
Pham, Jennifer
Brisson, Becky K.
Park, SooHyun
Smith, Lucas R.
Liu, Min
Tian, Zuozhen
Hammers, David W.
Vassilakos, Georgios
Sweeney, H. Lee
author_sort Barton, Elisabeth R.
collection PubMed
description INTRODUCTION: Dysferlin loss‐of‐function mutations cause muscular dystrophy, accompanied by impaired membrane repair and muscle weakness. Growth promoting strategies including insulin‐like growth factor 1 (IGF‐1) could provide benefit but may cause strength loss or be ineffective. The objective of this study was to determine whether locally increased IGF‐1 promotes functional muscle hypertrophy in dysferlin‐null (Dysf (−/−)) mice. METHODS: Muscle‐specific transgenic expression and postnatal viral delivery of Igf1 were used in Dysf (−/−) and control mice. Increased IGF‐1 levels were confirmed by enzyme‐linked immunosorbent assay. Testing for skeletal muscle mass and function was performed in male and female mice. RESULTS: Muscle hypertrophy occurred in response to increased IGF‐1 in mice with and without dysferlin. Male mice showed a more robust response compared with females. Increased IGF‐1 did not cause loss of force per cross‐sectional area in Dysf (−/−) muscles. DISCUSSION: We conclude that increased local IGF‐1 promotes functional hypertrophy when dysferlin is absent and reestablishes IGF‐1 as a potential therapeutic for dysferlinopathies.
format Online
Article
Text
id pubmed-6771521
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-67715212019-10-03 Functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin Barton, Elisabeth R. Pham, Jennifer Brisson, Becky K. Park, SooHyun Smith, Lucas R. Liu, Min Tian, Zuozhen Hammers, David W. Vassilakos, Georgios Sweeney, H. Lee Muscle Nerve Basic Science Research Articles INTRODUCTION: Dysferlin loss‐of‐function mutations cause muscular dystrophy, accompanied by impaired membrane repair and muscle weakness. Growth promoting strategies including insulin‐like growth factor 1 (IGF‐1) could provide benefit but may cause strength loss or be ineffective. The objective of this study was to determine whether locally increased IGF‐1 promotes functional muscle hypertrophy in dysferlin‐null (Dysf (−/−)) mice. METHODS: Muscle‐specific transgenic expression and postnatal viral delivery of Igf1 were used in Dysf (−/−) and control mice. Increased IGF‐1 levels were confirmed by enzyme‐linked immunosorbent assay. Testing for skeletal muscle mass and function was performed in male and female mice. RESULTS: Muscle hypertrophy occurred in response to increased IGF‐1 in mice with and without dysferlin. Male mice showed a more robust response compared with females. Increased IGF‐1 did not cause loss of force per cross‐sectional area in Dysf (−/−) muscles. DISCUSSION: We conclude that increased local IGF‐1 promotes functional hypertrophy when dysferlin is absent and reestablishes IGF‐1 as a potential therapeutic for dysferlinopathies. John Wiley & Sons, Inc. 2019-07-30 2019-10 /pmc/articles/PMC6771521/ /pubmed/31323135 http://dx.doi.org/10.1002/mus.26641 Text en © 2019 The Authors. Muscle & Nerve published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Basic Science Research Articles
Barton, Elisabeth R.
Pham, Jennifer
Brisson, Becky K.
Park, SooHyun
Smith, Lucas R.
Liu, Min
Tian, Zuozhen
Hammers, David W.
Vassilakos, Georgios
Sweeney, H. Lee
Functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin
title Functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin
title_full Functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin
title_fullStr Functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin
title_full_unstemmed Functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin
title_short Functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin
title_sort functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin
topic Basic Science Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771521/
https://www.ncbi.nlm.nih.gov/pubmed/31323135
http://dx.doi.org/10.1002/mus.26641
work_keys_str_mv AT bartonelisabethr functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin
AT phamjennifer functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin
AT brissonbeckyk functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin
AT parksoohyun functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin
AT smithlucasr functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin
AT liumin functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin
AT tianzuozhen functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin
AT hammersdavidw functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin
AT vassilakosgeorgios functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin
AT sweeneyhlee functionalmusclehypertrophybyincreasedinsulinlikegrowthfactor1doesnotrequiredysferlin